Eli Lilly shortlists for UK public affairs

The UK arm of US-based pharmaceutical company Eli Lilly, which produces the anti-depressant Prozac, has drawn up a shortlist for its public affairs account.

The UK arm of US-based pharmaceutical company Eli Lilly, which

produces the anti-depressant Prozac, has drawn up a shortlist for its

public affairs account.



GJW, APCO Associates, Bruce Naughton Wade and Grandfield are all in the

running for the account, which is rumoured to be worth between pounds

40,000 and pounds 50,000 in fees.



The review of Lilly’s public affairs activity follows the arrival of

Stephen Whitehead as director of corporate affairs in February.

Whitehead was previously director of external affairs at GrandMet.



Whitehead said the public affairs brief would include raising Lilly’s

profile in Government, monitoring the Government’s plans for the future

of the NHS and healthcare policy, and focus on alliance building.

’Considering the size of the company we don’t have much of a profile at

the moment,’ he said.



Lilly’s best-known product Prozac has a one third share of the

anti-depressant market in the UK. The company also produces the

schizophrenia treatment Zyprexa and the insulin product Humalog. It

claims to be the UK’s seventh largest drugs company.



Public affairs was previously handled by Edelman, which declined to

repitch for the account. Edelman, Cohn and Wolfe and Fleishman-Hillard

all handle product work for Lilly in the UK.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.